Abstracts A149 increasing per pack taxes by at least 10%, but smokers' lives were slightly extended by the ban condition. Incremental cost effectiveness ratios for taxes and bans, relative to no intervention were: $29,827 and $29,814 per life year gained, respectively. CONCLUSIONS: Both public policy strategies of taxes and bans have a minimal impact on life years gained over the lifetimes of smokers. Taxes showed an advantage in lower hospitalization and value of lives saved. In addition, taxes are revenue enhancing, while bans require additional enforcement resources. Using tobacco taxes to reduce tobacco consumption and subsequent tobacco-related disease is superior to smoking bans, though the combination of the two policies may be mutually reinforcing for behavioral change and additive in effect. OBJECTIVES: Clopidogrel is a frequently used drug to prevent subsequent atherothrombotic events in patients with stroke, myocardial infarction, or peripheral arterial diseases. Doctors should subjectively determine whether the price of clopidogrel is justifi ed by its improved therapeutic effect compared to that of aspirin, considering country-wise economic situation. This study analyzed the cost-effectiveness of clopidogrel for atherothrombosis treatment in South Korea. METHODS: Costeffectiveness was analyzed using the Cambridge model; a Markov model developed using data from the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study, as per Korean situation. The effect was estimated using data from the Framingham and Saskatchewan databases to calculate the expected survival (in years) for various health states. Direct medical costs from the social perspective, direct non-medical costs, and indirect medical costs were analyzed; applying 5% discount rate to both cost and effect. RESULTS: The 2-year follow-up results showed that the number of cardiovascular (CV) events and CV deaths per 1000 patients was decreased by 13.19 and 2.21, respectively, in the clopidogrel group as compared to the aspirin group. As clopidogrel treatment decreased the incidence of CV deaths; the number of life-years gained per 1000 patients was 65.65 (Framingham) and 48.20 (Saskatchewan). The incremental cost-effectiveness ratio determined using incremental costs per life-year gained was US$ 19,017 (Framingham) and US$ 25,904 (Saskatchewan). CONCLUSIONS: Our results showed that clopidogrel was cost-effective treatment of atherothrombosis in South Korea, and evaluated a basis for the economic feasibility of clopidogrel administration for atherothrombosis treatment.
PCV45 ECONOMIC ANALYSIS OF THE INSERTABLE CARDIAC MONITOR IN DIAGNOSIS OF SYNCOPE COMPARED TO CONVENTIONAL DIAGNOSTICS: A CANADIAN PERSPECTIVE
Sadri H 1 , Tsintzos S 2 , Winsor P 3 , Yee R 4 1 Medtronic of Canada Ltd, Toronto, ON, Canada, 2 Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland, 3 Medtronic of Canada, Mississauga, ON, Canada, 4 London Health Sciences Centre, London, ON, Canada OBJECTIVES: Syncope is a signifi cant burden on the health care system and individuals. Screening manoeuvres including medical examination, ambulatory external monitoring, imaging and clinical diagnostic tests provide a presumptive diagnosis in a limited number of patients since syncope recurrence is unpredictable. Establishing or ruling out a cardiac arrhythmia as the cause is challenging, time consuming and relies on recording the cardiac rhythm at the time of spontaneous recurrences. The Insertable Cardiac Monitor(ICM) is a new, effi cient and accurate technique for long-term monitoring and recording the "events" in a patient. This study assesses the costeffectiveness of adding the ICM to the standard diagnostic protocol in Canadian health care system. METHODS: A decision analytic model was developed assessing the cost-effectiveness of the standard diagnosis approach compared to ICM from a Canadian provider perspective. The main clinical outcome used in the model was "yield" defi ned as the rate of correct diagnoses derived from published literature. The frequency of resources used and associated costs were derived from literature and the Ontario Health Insurance Policy. RESULTS: The diagnosis yield for ICM and standard approach was 33.7% and 4.1% respectively. The model assessed the cost per diagnosis in the two arms. The incremental cost per diagnosis was $6237 in favour of ICM. Sensitivity analysis showed that in the lower confi dence interval (CI) the ICM is the "dominant" option and in upper CI limits the ICER was $35,358 and below the $50,000 acceptability threshold. CONCLUSIONS: ICM is a safe, accurate and effective device for diagnosis of syncope and should be considered as an alternative in diagnosis of syncope. The cost of ICM is partially offset by savings in hospitalization. A societal perspective will reduce the ICER in favour of ICM by preventing complications of syncope (i.e., falls, fractures, mortality) and increase patient HRQoL.
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COST-EFFECTIVENESS AND BUDGET IMPACT OF INTRODUCING FLUVASTATIN XL 80 MG INTO THE BRAZILIAN NATIONAL DRUG FORMULARY
Godoy MR 1 , Bueno RLP 2 , Suzuki C 3 1 UFRGS -Federal University of Rio Grande do Sul, São Paulo, São Paulo -SP, Brazil, 2 FEI, São Paulo, Brazil, 3 Novartis Biociências S/A, São Paulo, Brazil OBJECTIVES: To determine the cost-effectiveness, from the Brazilian Ministry of Health perspective, of Fluvastatin IR 20 mg, Fluvastatin IR 40 mg, Fluvastatin IR 80 mg and Fluvastatin XL 80. Also we calculated the budget impact of introducing Fluvastatin XL 80 mg into the current Brazilian national drug formulary. METHODS: The cost effectiveness was determined using clinical data from published systematic review and cost the costs were valued using government prices. The costs was in Brazilian reais (BRL) and the price year was 2008 (1$US 1.63 BRL). The benefi t measure used in this economic evaluation was LDL-reduction. Using the Healtchare System database' data we described the evolution of consumption of statins in Brazilian Health System. Univariate sensitivity analysis tested model robustness. We calculated the budget impact analysis for three years. RESULTS: The Fluvastatin XL 80 mg is the statin more cost-effective and permits the cost reduction in BRL $26,10 per patient. The sensitivity analysis of budget impact show that introduction Fluvastatin into formulary could generate average savings of 18% of the Fluvastatin's total budget or BRL 56,500 ($US 34,600). CONCLUSIONS: The inclusion of Fluvastatin XL 80 mg is aligned with the health authority strategy of cost containment or reduction for this class of medicines. Results are sensitive to the list price of drugs.
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COST-EFFECTIVENESS OF ADD-ON EARLY STRESS MYOCARDIAL PERFUSION IMAGING FOR ASIAN PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT WITH CHEST PAIN BUT NON-DIAGNOSTIC ELECTROCARDIOGRAPHY -THE ACUTE CHEST PAIN TREATMENT & EVALUATION STUDY (ACTION)
Ow MY 1 , Lim SH 2 , Chua TS 3 , Wee HL 1 1 National University of Singapore, Singapore, Singapore, 2 Singapore General Hospital, Singapore, Singapore, 3 National Heart Centre Singapore, Singapore, Singapore OBJECTIVES: Existing triage strategy is suboptimal in risk stratifying Asian patients with chest pain. Hence, we aim to determine the cost-effectiveness of an addon stress myocardial perfusion imaging (MPI) in improving risk stratifi cation in a single-centre randomized controlled trial involving Asian patients with chest pain and non-diagnostic ECG presenting to an emergency department (ED) in Singapore. METHODS: Consenting patients were randomly assigned to with or without MPI add-on. Patients who developed ST segment changes, elevated CKMB/ Troponin during the 6-hr observation were admitted without receiving the assigned interventions. One-year cost-effectiveness of the two strategies (MPI vs. no MPI) was analysed from the institution's perspective. Inpatient costs were obtained from electronic database. Outpatient costs were estimated with expert input. Effectiveness was measured as percent patients accurately risk stratifi ed at one year (i.e. high/medium risk patients experiencing a cardiac event and low risk patients not experiencing any cardiac event within one year). The incremental cost-effectiveness ratio (ICER) and confi dence intervals (CI) were constructed by bootstrap analysis (percentile approach). Sensitivity analysis was conducted for outpatient costs. RESULTS: Cost data were available from 1418 patients (83.9% of randomized patients). The ICER of MPI vs. no MPI was $6,334 ( $13,474 to $40). 97.6% of bootstrapped replicates fell below the $0 per accurate risk stratifi cation level, indicating that the scan strategy dominated the no scan strategy. All bootstrap replicates fell in the north-and south-east quadrants on the cost-effectiveness plane, confi rming that the negative ICER was due only to negative cost differences. Coeffi cient of variation (CV) of the effect difference is 0.19. Small bias to standard error ratio (0.013) justifi es not making bias correction in estimating CI. Results were insensitive to outpatient costs. CONCLUSIONS: Add-on MPI is cost-effective in risk stratifying patients with chest pain. Given the small CV, bootstrap estimates are likely to be robust.
PCV48 USING EXPERT ELICITATION TO INFORM ADOPTION AND RESEARCH DECISIONS FOR ENHANCED EXTERNAL COUNTERPULSATION IN ANGINA
McKenna C, Claxton K, Hawkins NS, Sculpher M University of York, York, UK OBJECTIVES: To demonstrate how expert elicitation can be combined with Bayesian decision theory to inform the decision to conduct further research and identify effi cient research design when there is limited evidence available. METHODS: Using a model of enhanced external counterpulsation (EECP) for the treatment of angina, expert elicitation was used to provide informed priors on the key model parameters where no evidence was available. These priors were updated with sample information to quantify the expected value of sample information (EVSI). The EVSI was compared to the costs of sampling and the expected net benefi t of sample information was obtained (ENBS). The ENBS is a measure of the societal payoff to research and provides a suffi cient condition for deciding to conduct more research. Given the need to establish if EECP has a role for treating angina and the paucity of effectiveness evidence available, the ENBS was used to determine the type of study required, the optimal sample size, the appropriate length of follow-up and the endpoints that should be included. RESULTS: There is signifi cant value to future research in EECP. This research is most valuable when directed towards establishing the
